<PAGE>
                                  United States
                       SECURITIES AND EXCHANGE COMMISSION

                            Washington, D.C. 20549
                                    FORM 10-Q


 (Mark One)

 [X]  QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
      ACT OF 1934


 For the quarterly period ended April 30, 1998
                                --------------


 [  ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
      EXCHANGE ACT OF 1934


 For the transition period from:              to
                                --------------   -------------

 Commission file number:  0-5958
                          ------
                       MERIDIAN MEDICAL TECHNOLOGIES, INC.
               (Exact name of registrant as specified in its charter)


           Delaware                              52-0898764
           --------                              ----------
 (State or other jurisdiction of              (IRS Employer
  incorporation or organization)               Identification No.)

 10240 Old Columbia Road, Columbia, Maryland       21046

 -------------------------------------------       -----
 (Address of principal executive offices)         (Zip Code)

 Registrant's telephone number, including area code:         410-309-6830
                                                             ------------

 Indicate by check mark whether the Registrant (1) has filed all reports
 required to be filed by Section 13 or 15(d) of the Securities Exchange Act of

 1934 during the preceding 12 months (or for such shorter period that the
 registrant was required to file such reports), and (2) has been subject to
 such filing requirements for the past 90 days.

                         YES [X]        NO [  ]

 Indicate the number of shares outstanding of each of the issuer's classes of

 common stock, as of the latest practicable date.

      Class                              Outstanding as of June 3, 1998
 ----------------------------            ------------------------------
 Common Stock, $.10 par value                 2,980,395 Shares

 <PAGE>


                                MERIDIAN MEDICAL TECHNOLOGIES, INC.
                                          FORM 10-Q
                                                               Page No.
                                                               --------

 PART I.  FINANCIAL INFORMATION
 ------------------------------
 ITEM 1.   Financial Statements (Unaudited except July 31, 1997 balance sheet)

          Consolidated Balance Sheets as of
            April 30, 1998 and July 31, 1997   ........................ 4

          Consolidated Statements of Operations for

            the Three and Nine Months Ended April 30, 1998 and 1997 .  .5

          Consolidated Statements of Cash Flows for
            the Nine Months Ended April 30, 1998 and 1997 ............. 6

          Notes to Consolidated Financial Statements .................. 7


 ITEM 2.  Management's Discussion and Analysis of Financial
            Condition and Results of Operations ...................... 10

 ITEM 3  Quantitative and Qualitative Disclosure about Market Risk ....14


 PART II. OTHER INFORMATION
 --------------------------


 ITEM 2   Changes in Securities and Use of Proceeds ...................14
 ITEM 6.  Exhibits and Reports on Form 8-K ........................... 14

 SIGNATURES........................................................... 15

 <PAGE>


                        MERIDIAN MEDICAL TECHNOLOGIES, INC.
                                   FORM 10-Q


 Meridian Medical Technologies, Inc. (hereinafter referred to as the _Company_
 or _MMT_ or _Meridian_) was formed in November 1996 through the merger of
 Survival Technology, Inc. (_STI_) and Brunswick Biomedical Corporation

 (_Brunswick_).  At the time of the merger, Brunswick held approximately 61%
 of STI's outstanding common stock, which Brunswick purchased from the estate
 of STI's late founder on April 15, 1996.  As a result, STI had been treated
 for financial accounting purposes as a consolidated, majority-owed subsidiary
 of Brunswick from that date.

 Although STI was the surviving corporation of the merger as a legal matter,
 the merger was treated as a purchase of STI by Brunswick for financial
 accounting purposes.  As a result, Brunswick's historical financial
 statements became the Company's financial statements, STI's assets and
 liabilities were revalued to their respective fair values and the Company's
 historical financial statements reflect the combined operations of STI and
 Brunswick after April 15, 1996 (subject to minority interests).  The minority
 interests was eliminated upon completion of the merger on November 20, 1996.


 MMT's business plan is to operate as a medical device company focusing on
 Home Healthcare and Emergency Medical Technologies.  The Company has three
 areas of business. The Drug Delivery Systems business capitalizes on
 injectable drug delivery devices with an emphasis on commercial auto-
 injectors.  This group also supplies customized drug delivery system design,
 pharmaceutical research and development, and sterile product manufacturing to
 pharmaceutical and biotechnology companies.  The Cardiopulmonary Systems
 business focuses on non-invasive cardiac diagnostics and telemedicine.  It is
 proceeding with the research and development of the PRIME ECG-TM- program, an
 80-lead cardiac mapping system for rapid and improved diagnostic accuracy of
 cardiac ischemia.  The STI Military Systems business focuses on the worldwide
 market for auto-injectors used by military personnel for self-administration
 of a family of nerve gas antidotes, morphine and diazepam, and civil defense
 applications.

 Certain statements in the Quarterly Report on Form 10-Q are forward-looking
 and are identified by the use of forward-looking words or phrases, such as,
 "believes," "expects," is or are "expected," "anticipates," "anticipated,"
 and words of similar import.  These forward-looking statements are based on
 the Company's current expectations.  Because forward-looking statements
 involve risk and uncertainties, the Company's actual results could differ
 materially.  In addition to the factors discussed generally herein, among the
 factors that could cause results to differ materially from current
 expectations are: (i) the general economic and competitive conditions in
 markets and countries where the Company and its subsidiaries offer products
 and services; (ii) changes in capital availability or costs; (iii)
 fluctuations in demand for certain of the Company's products, including
 changes in government procurement policy; (iv) technological challenges
 associated with the development and manufacture of current and anticipated
 products; (v) commercial acceptance of auto-injectors and competitive
 pressure from traditional and new drug delivery methods; and (vi) delays,
 costs and uncertainties associated with government approvals required to
 market new drugs and medical devices.

 <PAGE>


                        MERIDIAN MEDICAL TECHNOLOGIES, INC.
                                   FORM 10-Q
 PART I. FINANCIAL INFORMATION
 ITEM 1.  Financial Statements
      (in thousands of dollars)
<TABLE>

                               CONSOLIDATED BALANCE SHEETS

 <CAPTION>
                                                         April 30,
                                                           1998                  July 31,
                                                         (Unaudited)               1997
                                                         -----------             --------
                                                         <C>                     <C>
<S>
                        ASSETS

Current assets:
      Cash                                               $     279               $    23
      Restricted cash                                          264                   264
      Receivables                                            8,485                 7,507
      Inventories                                            8,440                 6,047
      Prepaid expenses and other assets                      1,031                   531
      Deferred income taxes                                  1,659                 1,659

                                                         --------                -------
           Total current assets                             20,158                16,031
                                                         --------                -------

 Fixed assets                                               19,322                17,246
      Less accumulated depreciation                          2,959                 1,468
                                                         --------                -------
                                                            16,363                15,778

                                                         --------                -------

 Deferred financing fees                                       729                    --
 Excess of cost over net assets acquired                     8,370                 9,168
 Other intangible assets                                     2,809                 3,105
                                                         --------                -------
           Total assets                                  $  48,429               $44,082

                                                         ========                =======

            LIABILITIES AND SHAREHOLDERS' EQUITY
 Current liabilities:
      Accounts payable and other accrued liabilities     $   7,604               $ 6,194
      Lines of credit                                        2,057                 4,113
      Current portion of long-term debt                        536                 2,299
      Product exchange reserves                              2,882                 1,539

      Customer deposits                                        221                   918
      Restructuring reserve                                    123                   124
                                                         --------                -------
           Total current liabilities                        13,423                15,187

      Long-term notes payable                               18,608                13,062
      Other long-term debt                                     535                   859

      Deferred revenue                                          --                   315
      Other noncurrent liabilities                             553                   625
                                                         --------                -------
      Deferred income taxes                                  1,741                 1,741
                                                         --------                -------
                                                            34,860                31,789
                                                         --------                -------


 Shareholders' equity:
      Common stock $.10 par, 18,000,000 authorized,
        2,980,395 and 2,912,502 issued and outstanding         298                   292
      Paid-in capital                                       28,851                28,660
      Warrants                                               3,003                 2,073

      Accumulated deficit                                 (18,269)               (18,312)
      Unearned stock option compensation                     (139)                  (140)
      Foreign currency translation adjustment                   38                   (67)
      Treasury stock, at cost                                (213)                  (213)
                                                         --------                -------
        Total shareholders' equity                          13,569                12,293
                                                         --------                -------
        Total liabilities and shareholders' equity       $  48,429               $44,082

                                                         ========                =======
 </TABLE>
 See accompanying notes to consolidated financial statements.
<PAGE>

                        MERIDIAN MEDICAL TECHNOLOGIES, INC.

                                   FORM 10-Q


                      CONSOLIDATED STATEMENTS OF OPERATIONS
                                    (Unaudited)
                (in thousands of dollars, except per share data)
<TABLE>
 <CAPTION>


                                                   Three-Months Ended                 Nine-Months Ended
                                                        April 30,                          April 30,
                                                      1998           1997                1998           1997
                                                   --------       --------            --------       --------
                                                 <C>            <C>                 <C>            <C>
 <S>
 Net sales                                       $   13,430     $   10,680          $   34,796       $ 29,663
 Cost of sales                                        8,324          6,875              21,220         18,843

                                                 ---------      ----------           ---------       ---------

      Gross profit                                    5,106          3,805              13,576         10,820
                                                 ----------     ----------          ----------       ---------
 Selling, general & administrative expense            1,735          1,450               4,676          4,325
 Research & development expense                         491            655               1,266          2,311
 Depreciation and amortization expense                  870            738               2,635          2,185

 Write-off in-process R&D                                --             --                  --          2,702
 Write-off merger transaction costs                      --             --                  --          1,246
 Product exchange                                     2,244             --               2,244             --
                                                 ----------     ----------          ----------       ---------
                                                      5,340          2,843              10,821         12,769
                                                 ----------     ----------          ----------       ---------

 Operating income (loss)                               (234)           962               2,755          (1,949)
                                                 ----------     ----------          ----------       ---------
 Other expense (income):
      Interest expense                                  694            323               2,083          1,929
      Other expense (income)                             13             50                (181)            (74)
                                                 ----------     ----------          ----------       ---------
                                                        707            373               1,902          1,855


 Income (loss) before income taxes and
 extraordinary loss                                    (941)           589                 853          (3,804)
 Provision (benefit) for income taxes                  (223)            --                 317            367
 Minority interest in consolidated subsidiary            --             --                  --            265
                                                 ----------     ----------          ----------       ---------

 Income (loss) before extraordinary loss               (718)           589                 536          (4,436)


 Extraordinary loss due to extinguishment of
  debt, net of income taxes of $317                     494             --                 494             --
                                                 ----------     ----------          ----------       ---------

 Net income (loss)                                   (1,212)    $      589                  42       $  (4,436)
                                                 ==========     ==========          ==========       =========


 Earnings per common share:
      Income (loss) before extraordinary item          (.24)          0.20                 .18           (2.69)
      Extraordinary charge                             (.17)            --                (.17)            --
                                                 ----------     ----------          ----------       ---------
      Net income per common share                $     (.41)    $     0.20          $      .01       $   (2.69)
                                                 ==========     ==========          ==========       =========
 Earnings per common share assuming dilution:
      Income (loss) before extraordinary item          (.24)          0.18                 .16           (2.69)

      Extraordinary charge                             (.17)            --                (.15)            --
                                                 ----------     ----------          ----------       ---------
      Net income per common share assuming
        dilution                                 $     (.41)    $     0.18          $      .01       $    (2.69)
                                                 ==========     ==========          ==========       ==========

 Weighted average shares:
      Basic                                       2,972,968      2,912,502           2,965,904       1,648,464
      Diluted                                     2,972,968      3,220,996           3,322,374       1,648,464

 </TABLE>


 See accompanying notes to consolidated financial statements.
<PAGE>

                        MERIDIAN MEDICAL TECHNOLOGIES, INC.

                                   FORM 10-Q


                      CONSOLIDATED STATEMENTS OF CASH FLOWS
                                  (Unaudited)
                           (in thousands of dollars)
<TABLE>
 <CAPTION>


                                                           Nine Months Ended
                                                               April 30,
                                                         1998               1997
                                                         ----               ----
                                                        <C>               <C>
 <S>
 Cash flows from operating activities:
      Net income (loss)                                $        42      $   (4,436)

 Adjustments to reconcile net income (loss) to net
      cash provided  by operating activities
      Depreciation and amortization                          2,635            2,247
      Amortization of deferred compensation                     56               54
      Amortization of notes payable discount                   876              398
      Loss (gain) on fixed asset disposals                      22              (7)
      Write off in-process R&D                                  --            2,702

      Provision for income taxes                               317              367
      Deferred interest to note principal                       --              757
      Extraordinary loss due to extinguishment of debt         494               --
      Changes in assets and liabilities
      Receivables                                            (978)              567
      Inventories                                          (2,393)             (947)
      Prepaid expenses and other assets                      (500)              141
      Accounts payable and accrued liabilities               2,752            1,542

      Restructuring reserve                                     --             (378)
      Other liabilities and accrued expenses                 (631)             (748)
      Deferred revenue                                       (315)              285
      Other noncurrent assets                                   --             (354)
      Other noncurrent liabilities                            (72)               78
                                                       ----------        ----------
      Net cash provided by operating activities              2,305            2,268

                                                       ----------        ----------

 Cash flows from investing activities:
      Purchases of fixed assets                            (2,165)           (2,505)
      Purchases of patents and licenses                         --              (55)
      Increase in short-term investments                        --              257
      Proceeds from sale of fixed assets                        --                3
                                                       ----------        ----------

      Net cash (used for) investing activities             (2,165)           (2,300)
                                                       ==========        ==========
 Cash flows from financing activities:
      Net (payment) proceeds on line of credit             (2,056)              716
      Proceed from refinanced notes payable long-term       14,070               --
      Payment on notes payable long-term                  (11,973)             (138)
      (Net payment) on other long-term debt                  (324)           (1,400)

      Proceeds from issuance of warrants                       930               --
      Payment of financing fees                              (729)               --
      Proceeds from issuance of common stock                   198               --
                                                       ----------        ----------

      Net cash provided by (used for)
        financing activities                                   116             (822)
                                                       ----------        ---------


 Net increase (decrease) in cash                               256             (854)
      Cash at beginning of period                               23            1,489
                                                       ----------        ----------
      Cash at end of period                            $       279       $      635

                                                       ==========        ==========

 </TABLE>

 See accompanying notes to consolidated financial statements.
 <PAGE>

                        MERIDIAN MEDICAL TECHNOLOGIES, INC.

                                   FORM 10-Q

 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 1.   In the opinion of management, the accompanying unaudited consolidated
      financial statements contain all adjustments (consisting of normal
      recurring accruals other than accruals for the product recall) necessary
      to present fairly the Company's financial position as of April 30, 1998

      and July 31, 1997, the results of its operations for the three-month and
      nine-month periods ended April 30, 1998 and 1997, and its cash flows for
      the nine-month periods ended April, 1998 and 1997.  The results of
      operations for the three-month and nine-month periods ended April 30,
      1998 are not necessarily indicative of the results that may be expected
      for the fiscal year ending July 31, 1998.


 2.   On November 20, 1996, Brunswick Biomedical Corporation ("Brunswick") was
      merged into Survival Technology, Inc. ("STI") to form Meridian Medical
      Technologies, Inc. ("MMT" or the "Company").  At the time of the merger,
      Brunswick held approximately 61% of STI's outstanding common stock, which
      it had purchased from the estate of STI's late founder on April 15, 1996.
      As a result, STI had been treated for financial accounting purposes as a
      consolidated, majority-owned subsidiary of Brunswick from that date and
      Brunswick's historical financial statements became the Company's

      financial statements, STI's assets and liabilities have been revalued to
      their respective fair values and Brunswick's historical financial
      statements reflect the combined operations of STI and Brunswick after
      April 15, 1996 (subject to minority interests).  The minority interests
      were eliminated upon completion of the merger on November 20, 1996.  (See
      Meridian's Annual Report on Form 10-K for fiscal year ended July 31, 1997
      for a more complete discussion of the merger accounting.)


 3.   Inventories consisted of the following (in thousands of dollars):

                                     April 30,        July 31,
                                       1998            1997
                                    --------------------------
      Components and subassemblies  $  6,283         $   4,788
      Material, labor and overhead

       costs in process                2,502             1,460
      Finished goods                     224               345
                                    ---------        ---------
                                    $  9,009         $   6,593

      Inventory reserve                 (569)            (547)
                                    ---------        ---------

      Total                         $  8,440         $   6,046


 <PAGE>

                        MERIDIAN MEDICAL TECHNOLOGIES, INC.
                                   FORM 10-Q


 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

 4.    On April 30, 1998, the Company sold $15.0 million aggregate principal
   amount of senior subordinated notes maturing on April 30, 2005 to Nomura
   Holding America Inc.  The notes bear 12% interest payable quarterly in
   arrears with principal payments deferred until maturity.  The Company
   issued warrants to Nomura Holding America Inc. to purchase 204,770 shares
   of MMT common stock until maturity of the notes at an exercise price of
   $11.988 per share (subject to an anti-dilution provision).

   The note proceeds were used to (1) retire $6.0 million of senior
   subordinated notes issued to the Sarnoff Estate which bore 13% interest
   and would have matured on April 15, 2001, (2) retire $1.2 million of
   subordinated notes issued to EM Industries which bore 13% interest and
   would have matured on April 15, 2001, and (3) reduce the existing senior
   term loan due ING CAPITAL by $3.5 million.  The senior term loan also was
   amended to extend its maturity to April 30, 2003, defer quarterly
   principal amortization payments until March 31, 1999 at which time
   quarterly amortizations will be $250,000 through March 31, 2002 with
   quarterly payments of $500,000 required thereafter.  Net of financing
   related costs of $700,000, the Company gained working capital borrowing
   availability of $3.5 million on its existing working capital line of
   credit with ING CAPITAL.  Associated with the refinancing transactions,
   the Company recorded an extraordinary charge on extinguishment of debt
   amounting to $494,000, net of an income tax benefit of $317,000.

 5.    On October 8, 1997, the Company announced a product exchange program for
   all of its EpiEZPen-Registered Trademark- product sold since March 1996
   (approximately 500,000 units).  This exchange program was initiated after
   a minimal amount of units (less than 10 units) were returned for premature
   activation in the package.  The estimated cost of the exchange program is
   $1.5 million and was included in fiscal 1997 results of operations as
   reported in the Company's Annual Report on Form 10-K.  Actual costs could
   differ materially from management's estimates; however, it now appears
   that the reserve will be adequate.  The Company has not included any cost
   sharing of this exchange with potentially responsible parties as the
   benefit and probability of such an arrangement are not determinable at
   this time. Actual costs incurred through April 30, 1998 were approximately
   $901,000. The Company believes the exchange will be substantially complete
   by the end of fiscal 1998.

 6.    On May 8, 1998, the Company announced a Class 1 product recall for 47 
   lots of EpiPen-Registered Trademark- auto-injectors manufactured between June
   1997 and February 1998 (approximately 1.0 million units).  This recall was
   initiated after detecting a loss of active drug (epinephrine) in retained
   samples from production lots.  The loss of epinephrine resulted from a
   chemical complex formed from exposure of the active drug to the needle
   caused by puncture of the drug cartridge diaphragm by the needle during an
   automated production step.  Upon detection of the puncture, the Company
   immediately terminated the automated production process and reverted back
   to the previous production process.  The estimated cost of the recall is
   $2.2 million and is included in the fiscal third quarter.  While the
   Company believes the estimated costs are reasonable to cover the cost of
   the recall, actual costs could differ materially from management's
   estimates.

 <PAGE>


                        MERIDIAN MEDICAL TECHNOLOGIES, INC.
                                   FORM 10-Q

 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)


 7.    In February 1997, the Financial Accounting Standards Board issued
   Statement No. 128, Earnings per Share, which was required to be adopted by
   the Company in its January 1998 financial statements.  The Company has
   adopted this methodology and used it to compute current earnings per share
   and to restate all prior periods.  Under the new requirements for
   calculating basic earnings per share, the dilutive effect of stock
   options, warrants and other potentially dilutive common shares are
   excluded.  Fully diluted EPS has not changed significantly but has been
   renamed diluted EPS.  The extraordinary loss due to extinguishment of debt
   was ($0.17) per basic and diluted share for the quarter and ($0.17) per
   basic and ($0.15) per diluted share for nine months ended April 30, 1998.

 8.    There is no current or deferred tax expense for the nine months ended
   April 30, 1998 due to the quarterly loss.  When applied to the estimated
   income tax for the fiscal year, the carryforwards are expected to reduce
   the effective rate to zero.
 <PAGE>

                        MERIDIAN MEDICAL TECHNOLOGIES, INC.
                                   FORM 10-Q


 ITEM 2.   Management's Discussion and Analysis of Financial Condition and
           Results of Operations

 The Quarter and Nine Months in Review


 MMT earned $651,000 or $0.22 basic and diluted earnings per share excluding a
 reserve provision for EpiPen-Registered Trademark- recall and an
 extraordinary loss on extinguishment of debt during the three months ended
 April 30, 1998.  MMT incurred a net loss of $1.2 million, ($0.41) basic and
 diluted earnings per share (see Note 7 to the consolidated financial
 statements) on sales of $13.4 million for the third quarter of fiscal 1998
 ended April 30, 1998 compared with net income of $589,000 or $0.20 per basic
 and  $0.18 per diluted earnings per share, on sales of $10.7 million in the
 same period of fiscal 1997.  (The fiscal 1997 nine month shares shown in the
 Consolidated Statement of Operations are not comparable to fiscal 1998 due to
 the low common share base of Brunswick prior to the merger.)  The fiscal 1998
 third quarter net loss includes a $2.2 million ($1.4 million after tax)
 provision for a product recall and a $494,000 net of tax, extraordinary
 charge on extinguishment of debt.  Earnings before interest, taxes,
 depreciation and amortization (EBITDA) for the third quarter of fiscal 1998
 was $2.9 million (excluding the product recall provision and the
 extraordinary charge for extinguishment of debt) compared to $1.6 million for
 the same period in fiscal 1997.

 For the nine months ended April 30, 1998, MMT earned net income of $42,000 or
 $0.01 basic and diluted earnings per share on revenues of $34.8 million.
 These results compare to a net loss of ($4.4 million) or ($2.69) per basic
 and diluted share for the fiscal 1997 nine month comparable period.  The
 fiscal 1998 nine month net income includes a $2.2 million ($1.4 million after
 tax) provision for a product recall, and an extraordinary charge on
 extinguishment of debt amounting to $494,000 net of tax, while the nine month
 fiscal 1997 net loss includes $3.9 million of non-recurring, one-time merger
 related costs.  EBITDA for the first nine months of fiscal 1998 excluding the
 recall provision and the extraordinary loss on refinancing of debt was $7.8
 million compared to $4.2 million in the first nine months of fiscal 1997
 excluding merger related costs.

 Revenues of MMT's three areas of business and gross profit for the quarter
 and nine months ended April 30, 1998 and 1997 are as follows:
 <TABLE>
 <CAPTION>



           ($thousands)        Quarter ended       Quarter ended       Nine Months ended   Nine Months ended
                              April 30, 1998      April 30, 1997        April 30, 1998      April 30, 1997
                             <C>                 <C>                   <C>                 <C>
 <S>
 Drug Delivery                 $     4,493         $     4,831           $   15,869           $   13,904
 Cardiopulmonary                       314                 822                  844                2,370
 STI Military  Systems               8,623               5,027               18,083               13,389
                               -----------         -----------           ----------           -----------
 Total Revenues                $    13,430         $    10,680           $   34,796           $   29,663
                               ===========         ===========           ==========           ===========
 Gross Profit                  $     5,106         $     3,805           $   13,576           $   10,820
                               ===========         ===========           ==========           ===========

 Gross Profit %                      38.0%               35.6%                39.0%                36.5%

 </TABLE>
<PAGE>

                        MERIDIAN MEDICAL TECHNOLOGIES, INC.
                                   FORM 10-Q


 ITEM 2.   Management's Discussion and Analysis of Financial Condition and
           Results of Operations
           (continued)

 Drug Delivery business revenue in the fiscal third quarter ended April 30,
 1998 was $4.5 million compared to $4.8 million in the comparable prior year
 period.  The 6% lower revenue reflects primarily the absence of development
 revenue amounting to $900,000 from Mylan Laboratories for filing aNDA's,
 partially offset by EpiPen-Registered Trademark- shipments, which were 32%
 above prior year levels.  The growth in EpiPen-Registered Trademark-
 shipments was partially due to an adjustment in inventory levels from
 increased sales and marketing emphasis.


 Drug Delivery revenues for the first nine-months of fiscal 1998 were $15.9
 million, 14% higher than the comparable prior year period.  The increase is
 attributable to a 47% increase in EpiPen-Registered Trademark- revenues
 partially offset by the absence of Mylan aNDA development revenues.

 Impacting the Drug Delivery business is the May 8, 1998 Class 1 recall
 announced for the EpiPen-Registered Trademark-.  As explained in Note 6 to
 the consolidated financial statements, the recall involves 1.0 million units
 covering production from June 1997 through February 1998.  The Company is
 working closely with Dey Laboratories, the product distributor, to provide
 replacement products as well as satisfy growth in core product demand.  The
 Company's production facilities are operating at maximum capacity limited by
 component vendor delivery capabilities.  The reserve provision of $2.2
 million was estimated and is considered adequate to cover the full costs of
 the replacements.  However, no assurances can be given that this estimate is
 accurate.

 The Drug Delivery new product pipeline continued to expand during the third
 quarter.  On February 10, 1998 MMT entered into an alliance with DuoJect
 Medical Systems to provide diluent solution and assemble DuoJect's Inter-Vial
 drug delivery system.  The DuoJect system provides separate storage chambers
 for powdered medication and diluent that can then be combined within a single
 syringe system for application.  MMT will provide sterile filling of the
 diluent and assembly of the DuoJect system.  On March 10, 1998, MMT obtained
 North American rights to manufacture and co-market IntraJect-Registered
 Trademark-, a pre-filled, disposable, needle-less auto-injector developed by
 UK-based Weston Medical Ltd.  This patented technology provides MMT a
 strategic opportunity to further compliment its auto-injector portfolio and,
 if successful, to offer a significantly lower cost drug delivery device.  On
 April 28, 1998, MMT announced an agreement with Human Genome Sciences, Inc.
 (HGS) to supply product filled vials for use in HGS's Phase I and Phase II
 clinical trials for human protein Myeloid Progenitor Inhibitory Factor-1 for
 cancer therapy.  Revenues are anticipated this fiscal year.  Over the near
 term, the Company should realize increasing development revenues with a
 potential for product revenues in later years.

 Cardiopulmonary revenues were lower in the third quarter and nine months
 ended April 30, 1998 compared to the same periods of fiscal 1997 primarily
 due to the sale of a non-core emergency care product line previously included
 as part of the cardiopulmonary business and the absence of a CardioBeeper-
 Registered Trademark- promotion held in fiscal 1997.



 <PAGE>

                        MERIDIAN MEDICAL TECHNOLOGIES, INC.
                                   FORM 10-Q


 ITEM 2.   Management's Discussion and Analysis of Financial Condition and

           Results of Operations
           (continued)

 The Cardiopulmonary systems group PRIME ECG-TM- Electrocardiac Imaging System
 product development is proceeding towards a fiscal year 1999 European launch
 and a fiscal year 2000 U.S. launch.  Several potential U.S. partners have
 been identified and discussions are proceeding, but no assurances can be
 given that agreements will be reached or timetables achieved.  Contracts were
 let to facilitate the PRIME ECG-TM- FDA regulatory filing and to initiate
 clinical trials in the US.  Three scientific papers were presented and
 submitted in a recent American College of Cardiology annual convention.

 STI Military Systems revenues in the third quarter of fiscal 1998 were $8.4
 million, 67% higher than the same period last year.  The increased revenues
 were primarily from the U.S. DoD for pre-stocking components and shipments of
 auto-injectors to replenish supplies.  Partially offsetting these gains was
 the absence of a large auto-injector shipment to a NATO allied country in the
 third quarter of last year.

 Nine month revenues of the STI Military Systems group were $17.9 million, 33%
 higher than in the comparable prior year period.  The growth results from
 higher shipments to the U.S. DoD for pre-stocking of components and shipment
 of auto-injectors.

 Third quarter STI Military business activities included the approval for
 storage of morphine enabling the first shipments of morphine auto-injectors
 in the fiscal fourth quarter 1998.  The unit also completed the bio-
 availability clinical trial for the multi-chambered auto-injector with
 results expected by mid-summer.Additionally, orders were received from the
 City of New York for delivery of auto-injectors for civil defense, and an
 order was received from the Government of Israel for delivery of auto-
 injectors starting in the fiscal fourth quarter of this year and continuing
 into 1999.

 Gross margins were 38.0% and 39.0% of revenues in the third quarter and nine
 months ended April 30, 1998 respectively compared to 35.6% and 36.5% in the
 same periods of fiscal 1997.  The margin improvement is due to the increased
 revenues coupled with overhead cost control and continuing cost reduction
 programs.  The lower gross margins in the third quarter compared to the
 previous six months reflect mix changes, particularly high military pre-
 stocking shipments in the third quarter.

 Operating costs were $5.3 million in the third quarter of fiscal 1998, $2.5
 million higher than in the comparable period of fiscal 1997.  The higher
 costs primarily reflect the EpiPen-Registered Trademark- product recall
 provision of $2.2 million.  Operating costs were $10.8 million during the
 first nine months of fiscal 1998, $2.0 million less than in the comparable
 prior year period, which is mostly the result of higher contract R&D incurred
 by Brunswick prior to the merger.  Excluding the $2.2 million EpiPen-
 Registered Trademark- reserve provision in fiscal 1998 and the $3.9 million
 merger costs in fiscal 1997, operating costs were lower than prior year by
 $297,000.

 Operating income, excluding the EpiPen-Registered Trademark- product recall,
 was $2.0 million for the quarter ended April 30, 1998, $1.0 million higher
 than the comparable period in the prior year.  Operating income for the first
 nine months of fiscal 1998 was $5.0 million compared to $2.0 million in the
 prior year comparable period, excluding the recall provision in 1998 and the
 merger costs in 1997.

 <PAGE>

                        MERIDIAN MEDICAL TECHNOLOGIES, INC.
                                   FORM 10-Q



 ITEM 2.   Management's Discussion and Analysis of Financial Condition and
           Results of Operations
           (continued)

 Interest expenses were $694,000 in the third quarter of fiscal 1998, an
 increase of $371,000 over the prior year third quarter which was low due to
 an adjustment of interest cost, which was over accrued in the prior year
 second quarter.

 The income tax provision for the third quarter of fiscal 1998 was a credit of
 $540,000 consisting of a benefit of $223,000 from losses before extraordinary
 item, and a benefit of $317,000 for the extraordinary loss from the
 extinguishment of debt.  The nine month tax provision of $317,000 is
 completely offset by the tax benefit from the extraordinary loss.  The
 utilization of available net operating loss carryforwards of Brunswick 
 will likely offset any tax provision required for the year.  A tax provision
 for the first nine months of fiscal 1997 was made because the Company needed
 to provide for taxes on STI earnings prior to the merger.

 Liquidity and Capital Resources

 Total cash as of April 30, 1998 was $543,000, an increase of $256,000 from
 July 31, 1997.  The Company generated $2.3 million of cash from operations in
 the first nine months of fiscal 1998, despite net income of $42,000,
 attributable mostly to non-cash depreciation and amortization partially
 offset by cash used to fund working capital changes, primarily inventory and
 receivables.  Investing activities in the first nine months of fiscal 1998
 used $2.2 million of cash for capital additions mostly for molds, automation
 equipment associated with cost reduction projects and for a new autoclave.
 Net proceeds from the debt refinancing used to reduce the working capital
 line with ING CAPITAL was $3.5 million.

 During the nine months ended April 30, 1998, the Company increased its asset
 based working capital credit line with ING CAPITAL to a maximum of $6.5
 million from $5.0 million.  The amount outstanding under this working capital
 line at April 30, 1998 was $1.8 million.  On April 30, 1998, the Company
 completed its planned long-term debt refinancing.  The Company issued $15.0
 million of senior subordinated notes to Nomura Holding America Inc. (Nomura)
 and used the proceeds to retire and pay-down term notes issued to finance the
 merger which were currently requiring amortization principal payments.
 The senior subordinated notes to Nomura mature on April 30, 2005 and bear
 interest at 12% payable quarterly in arrears with principal payment deferred
 until maturity.  The Company issued warrants to Nomura to purchase 204,770
 shares of MMT common stock until maturity of the Notes at an exercise price
 of $11.988 per share.  The Company retired senior subordinated debt held by
 the Sarnoff Estate for $6.0 million, retired subordinated debt held by EM
 Industries for $1.2 million and paid down $3.5 million on the senior term
 loan with ING CAPITAL.  After these transactions, the Company eliminated
 quarterly principal amortization payments until March 31, 1999 and increased
 its cash borrowing availability through the working capital line by $3.5
 million.  (See Note 4 to the consolidated financial statements for discussion
 about the debt refinancing.)

 An initial grant award of $508,000 was received from the Industrial
 Development Board of Northern Ireland to assist MMT in its facility
 consolidation in Northern Ireland.  While no assurances can be given that all
 anticipated grants will be received, total expected grants for both capital
 and expense items associated with the facility consolidation in Northern
 Ireland will approach $1.3 million over three years.

 <PAGE>

                        MERIDIAN MEDICAL TECHNOLOGIES, INC.
                                   FORM 10-Q


 ITEM 2.   Management's Discussion and Analysis of Financial Condition and
           Results of Operations
           (continued)

 Working capital at April 30, 1998 was $7.8 million, up from $0.8 million at
 July 31, 1997.  The increase is primarily attributable to higher inventories
 ($2.4 million), higher receivables ($978,000), higher prepaid expenses
 ($500,000) and lower current liabilities ($1.8 million) mostly from reduced
 borrowings on the credit line.  At April 30, 1998, accounts receivable were
 $8.5 million, representing 66 days-sales-outstanding, and inventories were
 $8.4 million representing a turn-over rate of 3.4 times per year.

 ITEM 3.   Quantitative and Qualitative Disclosure about Market Risk

           Not applicable.


 PART II - OTHER INFORMATION


 ITEM 2.   Changes in Securities and Use of Proceeds

 Financial covenants under the 4th Amendment to the Term Loan and revolving
 credit loan with ING CAPITAL and the senior subordinated notes with Nomura
 Holding America Inc. described herein require the Company to maintain certain
 levels of net worth and debt to EBITDA ratios and limit the Company's capital
 expenditures in any one fiscal year to amounts varying from $3.8 million to
 $5.0 million under the ING agreement and $4.2 million to $6.6 million under
 the Nomura agreement.  In addition, covenants under such indebtedness
 restrict the ability of the Company to pay any dividends on its common stock.


 On April 30, 1998, for $930,000, the Company issued warrants to Nomura
 Holding America Inc to purchase 204,770 shares (subject to anti-dilution
 provision) of MMT common stock until April 30, 2005 at an exercise price of
 $11.988 per share (subject to dilution adjustment).  On April 30, 1998, for
 $14,070,000, the Company isued, to Nomura Holding America Inc.,12% Senior

 Subordinated Notes, with interest payable quarterly in arrears and principal
 due April 30, 2005.  The Company issued the Notes and the warrants in
 reliance on the exemption from registration under section 4(2) of The
 Securities Act of 1933, as amended.


 ITEM 6.   Exhibits and Reports on Form 8-K:


 (a)  Exhibits

      Exhibit 10.1 - Note and Warrant Purchase Agreement dated as of April 30,
                     1998.

      Exhibit 10.2 - Registration Rights Agreement dated as of April 30, 1998.


      Exhibit 10.3 - Warrant Agreement dated as of April 30, 1998.

      Exhibit 27.1 - Financial Data Schedule.

      Exhibit 27.2 - Restated Financial Data Schedule for the quarter ended
                     April 30, 1997

 (b)  Reports on Form 8-K


      Press releases dated May 8, 1998 issued by the Company were filed as
      exhibits 99.1 and 99.2 to Form 8-K filed and dated May 8, 1998.

 <PAGE>

                        MERIDIAN MEDICAL TECHNOLOGIES, INC.
                                   FORM 10-Q

                                   SIGNATURES


 Pursuant to the requirement of the Securities Exchange Act of 1934, the
 registrant has duly caused this report to be signed on its behalf by the
 undersigned thereunto duly authorized.


                                    MERIDIAN MEDICAL TECHNOLOGIES, INC.
      `                             -----------------------------------
                                         Registrant


           June 3, 1998                  By:  /S/James H. Miller
           ------------                  -----------------------
           Date                          James H. Miller
                                         President and
                                         Chief Executive Officer
                                         (Principal Executive Officer)


           June 3, 1998                  By:  /S/G. Troy Braswell
           ------------                  ------------------------
           Date                          G. Troy Braswell
                                         Vice President-Finance
                                         and Chief Financial Officer
                                         (Principal Financial and
                                          Accounting Officer)